不同剂量阿托伐他汀治疗不稳定型心绞痛的临床效果分析

Clinical effects of different doses of atorvastatin on patients with unstable angina

目的研究不同剂量阿托伐他汀治疗不稳定型心绞痛的临床效果。方法入选150例不稳定型心绞痛患者,随机分为两组,每组75例,其中对照组予以每日20 mg阿托伐他汀钙片治疗,而研究组采用每日40 mg阿托伐他汀钙片治疗,两组均同时予以冠心病二级预防治疗,治疗随访6个月后,比较两组相关临床资料。结果治疗1个月后,对照组的hs-CRP水平较治疗前明显降低(P<0.05),而研究组的LDL及hs-CRP水平较治疗前和同期对照组明显降低(P<0.05),其他血脂指标无显著变化(P>0.05);治疗6个月后,两组TC、TG、LDL及hs-CRP水平均较治疗前明显降低(P<0.05),同时,研究组的LDL、TG及hs-CRP水平均较对照组明显降低(P<0.05)。治疗6个月中,研究组的主要心血管事件发生率较对照组明显降低(P<0.05),两组均无明显不良反应发生。结论大剂量阿托伐他汀可以明显减少不稳定型心绞痛患者主要心血管事件的再发风险,可能与其显著降低血脂水平、减轻炎症反应有关。

Objective To investigate the clinical effects of different doses of atorvastatin on patients with unstable angina.Methods 150 patients with unstable angina were selected and randomly divided into two groups with 75 cases in each group. Control group was treated with 20 mg atorvastatin calcium tablet per day, and research group was treated with 40 mg atorvastatin calcium tablet per day. Both groups received coronary artery disease secondary prevention treatment at the same time. After the six-month treatment and follow-up, comparison was made in the clinical data between the two groups. Results After the treatment for one month, the hs-CRP level of the control group significantly decreased（P 〈 0.05）, while the LDL and hs-CRP levels of the research group decreased significantly compared with those before the treatment and those of the control group in the same time period（P 〈0.05）. Other blood fat indexes had no obvious changes（P 〉 0.05）. After the treatment for 6 months, the TC, TG, LDL, and hs-CRP levels of both groups significantly decreased（P 〈 0.05）. At the same time, the LDL, TG, and hs-CRP levels of the research group significantly decreased compared with those of the control group（P 〈 0.05）. During the 6 months of treatment, the incidence of major cardiovascular events（MACE） in the research group decreased significantly compared with that in the control group（P 〈 0.05）. There was no obvious adverse reaction occurred in either group. Conclusion Large dose of atorvastatin can obviously reduce the recurrence risk of MACE in patients with unstable angina, which may be correlated with its influence on the significant decrease of blood fat levels and the relieving of inflammatory reaction.